Study #2023-0710
Randomized, controlled, open-label, phase IIb/III study of Lurbinectedin in combination with Doxorubicin versus Doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma
MD Anderson Study Status
Enrolling
Treatment Agent
Lurbinectedin, Doxorubicin
Description
The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leiomyosarcoma
Study phase:
Phase II/III
Physician name:
Shreyaskumar Patel
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-866-397-2063
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.